Zuomei Li

发表

Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.

A. Kalita, A. Macleod, O. Moradei, 2006, Bioorganic & medicinal chemistry letters.

4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.

A. Kalita, M. Robert, O. Moradei, 2008, Bioorganic & medicinal chemistry letters.

Starch fermentation wastewater as a precursor to prepare S,N-doped carbon dots for selective Fe(III) detection and carbon microspheres for solution decolorization

Dong-lin Zhao, Fazhi Xie, Zuomei Li, 2020 .

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Sylvain Lefebvre, Daniel Delorme, A. Kalita, 2008, Molecular Cancer Therapeutics.

Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.

Daniel Delorme, A. Kalita, M. Robert, 2003, Journal of medicinal chemistry.

N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors.

M. Robert, A. Macleod, O. Moradei, 2007, Bioorganic & medicinal chemistry letters.

Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors

K. Gelmon, A. Tolcher, M. Carducci, 2005 .

The Class I Hdac Inhibitor Mgcd0103 Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Initiating Cells by Upregulating Dickkopf-1 and Non-Canonical Wnt Signaling

Steven M. Lipkin, Xiling Shen, S. Lipkin, 2010, Oncotarget.

Phosphatidylinositol 3-kinase-γ activates Bruton’s tyrosine kinase in concert with Src family kinases

P. Hawkins, O. Witte, Zuomei Li, 1997 .

Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B‐cell receptor activation

H. Ochs, J. Kinet, A. Scharenberg, 1998, The EMBO journal.

Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases

Xiang-Jiao Yang, Zuomei Li, J. Besterman, 2008, Expert opinion on drug discovery.

Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.

O. Moradei, S. Leit, S. Fréchette, 2007, Journal of medicinal chemistry.

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

M. Carducci, L. Siu, A. Kalita, 2008, Clinical Cancer Research.

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.

M. Carducci, L. Siu, A. Kalita, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model.

C. Wahlestedt, J. Timmons, Farzaneh Modarresi, 2022, Journal of Alzheimer's disease : JAD.

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

M. Minden, Z. Estrov, W. Miller, 2008, Blood.

Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors.

Eric Therrien, M. Fournel, Zuomei Li, 2015, Bioorganic & medicinal chemistry letters.

Inhibition d'histone deacetylase

A. Macleod, Zuomei Li, J. Besterman, 2000 .

SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).

A. Kalita, O. Moradei, S. Leit, 2009, Bioorganic & medicinal chemistry letters.

Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study

R. Martell, M. Crump, D. Rizzieri, 2008 .

Conformational Role of Gly Residues in Transmembrane Segments of Wild Type and Mutant M13 Coat Proteins

C. Deber, M. Glibowicka, Zuomei Li, 1992 .

Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)

R. Bociek, R. Martell, J. Kuruvilla, 2008 .

Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors

H. Hurwitz, E. Chan, B. Nelson, 2007 .

Pharmacodynamic effect of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, on HDAC enzyme inhibition and histone acetylation induction in phase I clinical trials in patients (pts) with advanced solid tumors or non-Hodgkin’s lymphoma (NHL)

K. Gelmon, A. Tolcher, M. Carducci, 2005 .

Evaluation of the Pharmacodynamic Effects of MGCD 0103 from Preclinical Models to Human Using a Novel HDAC

M. Carducci, L. Siu, A. Kalita, 2008 .

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

R. Stocco, A. Roulston, Jordan T. F. Young, 2021, Molecular Cancer Therapeutics.

Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.

C. Maroun, S. Leit, M. Fournel, 2009, Bioorganic & medicinal chemistry letters.

Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells.

S. Gal, M. Buschmann, A. Merzouki, 2012, Anticancer research.

Phosphatidylinositol‐3,4,5‐trisphosphate (PtdIns‐3,4,5‐P3)/Tec kinase‐dependent calcium signaling pathway: a target for SHIP‐mediated inhibitory signals

L. Cantley, I. Gout, J. Kinet, 1998, The EMBO journal.

Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.

A. Kalita, A. Macleod, S. Leit, 2002, Cancer research.

(2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors

A. Kalita, A. Macleod, O. Moradei, 2004 .

Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)

A. Yang, G. Garcia-Manero, C. Maroun, 2007 .

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Isabelle Paquin, Daniel Delorme, A. Kalita, 2008, Journal of medicinal chemistry.

Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.

Daniel Delorme, O. Moradei, S. Leit, 2002, Journal of medicinal chemistry.

(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.

A. Kalita, A. Macleod, O. Moradei, 2004, Bioorganic & medicinal chemistry letters.

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

R. Bociek, J. Paulus, Y. Oki, 2011, The Lancet. Oncology.

Immunostimulatory activity and structure of polysaccharide from Streptococcus equi subsp. zooepidemicus.

Xiaoxiong Zeng, Hong Ye, Zuomei Li, 2013, International journal of biological macromolecules.

Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.

P. Mclaughlin, A. Younes, R. Martell, 2007 .

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

R. Bociek, P. Mclaughlin, A. Younes, 2007 .

Phase II Study of Mocetinostat ( MGCD 0103 ) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma

R. Bociek, J. Paulus, Y. Oki, 2016 .

Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.

S. Leit, Zuomei Li, J. Rahil, 2009, Bioorganic & Medicinal Chemistry Letters.

Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors.

Alain Ajamian, Sylvain Lefebvre, Alina Nicolescu, 2009, Bioorganic & medicinal chemistry letters.

Sulfamides as novel histone deacetylase inhibitors.

Alain Ajamian, Sylvain Lefebvre, Alina Nicolescu, 2009, Bioorganic & medicinal chemistry letters.

Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.

A. Kalita, M. Robert, A. Macleod, 2008, Bioorganic & medicinal chemistry letters.

Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS).

M. Minden, Z. Estrov, G. Garcia-Manero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Packing of coat protein amphipathic and transmembrane helices in filamentous bacteriophage M13: role of small residues in protein oligomerization.

H. Li, C. Deber, D. Marvin, 1995, Journal of molecular biology.

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

J. Issa, A. Yang, H. Kantarjian, 2006 .

Design and synthesis of a novel class of histone deacetylase inhibitors.

S. Leit, S. Fréchette, G. Bouchain, 2001, Bioorganic & medicinal chemistry letters.

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

M. Minden, Z. Estrov, W. Miller, 2008, Blood.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

A. Kalita, M. Robert, A. Macleod, 2008, Molecular Cancer Therapeutics.

Val-->Ala mutations selectively alter helix-helix packing in the transmembrane segment of phage M13 coat protein.

C. Deber, M. Glibowicka, Z. Li, 1993, Proceedings of the National Academy of Sciences of the United States of America.

83 Antitumor activities of MGCD0103, a novel isotype-selective histone deacetylase inhibitor

R. Macleod, O. Moradei, Nancy Z. Zhou, 2004 .